SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-22-000333
Filing Date
2022-01-14
Accepted
2022-01-14 17:30:20
Documents
13
Period of Report
2021-08-10
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A reph-20210810.htm   iXBRL 8-K/A 52223
2 EX-99.1 reph-ex99_1.htm EX-99.1 216253
  Complete submission text file 0000950170-22-000333.txt   402309

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT reph-20210810.xsd EX-101.SCH 2496
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT reph-20210810_lab.xml EX-101.LAB 13316
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT reph-20210810_pre.xml EX-101.PRE 9834
7 EXTRACTED XBRL INSTANCE DOCUMENT reph-20210810_htm.xml XML 6554
Mailing Address 1 E. UWCHLAN AVE, SUITE 112 EXTON PA 19341
Business Address 1 E. UWCHLAN AVE, SUITE 112 EXTON PA 19341 770-534-8239
Recro Pharma, Inc. (Filer) CIK: 0001588972 (see all company filings)

IRS No.: 261523233 | State of Incorp.: PA | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36329 | Film No.: 22532808
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences